臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"shao y y"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 176-225 / 396 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-08-11T03:46:38Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2021-08-11T03:46:37Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:36Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-08-11T03:46:34Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2021-08-11T03:46:33Z	Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma	Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏	2021-08-10T03:53:02Z	A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma	SHIH-HUNG YANG; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2021-07-23T07:49:44Z	Right or left? Side selection for a totally implantable vascular access device: A randomised observational study	WEN-YING LIN; Lin C.-P.; Hsu C.-H.; Lee Y.-H.; Lin Y.-T.; Hsu M.-C.; Shao Y.-Y.
臺大學術典藏	2021-07-23T07:49:43Z	Solving the deficit of cancer pain management skills by education programs	Shao Y.-Y.; WEN-YING LIN; Lin C.-P.; Lu L.-C.; Hsu C.-H.
臺大學術典藏	2021-07-12T08:46:25Z	�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-07-03T03:34:48Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; PEI-JER CHEN; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-07-03T03:33:48Z	Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study	Lu L.-C.; PEI-JER CHEN; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L.
臺大學術典藏	2021-06-04T06:23:10Z	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS	Chiu H.-H.; Liao H.-W.; Shao Y.-Y.; Lu Y.-S.; Lin C.-H.; Tsai I.-L.; CHING-HUA KUO
臺大學術典藏	2021-06-01T07:03:09Z	Key opioid prescription concerns in cancer patients: A nationwide study	Lin C.-P.; Hsu C.-H.; WEN-MEI FU; Chen H.-M.; Lee Y.-H.; Lai M.-S.; Shao Y.-Y.
臺大學術典藏	2021-05-27T09:07:06Z	Emergency department presentation of chronic peritoneal dialysis patients	Pai M.-F.; Hsu S.-P.; Peng Y.-S.; CHIH-KANG CHIANG; Ho T.-I.; Shao Y.Y.; Lee H.-Y.; Hung K.-Y.
臺大學術典藏	2021-05-07T06:02:30Z	Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice	Liang Y.-H.;Shao Y.-Y.;Liao B.-C.;Lee H.-S.;Yang J.C.-H.;Chen H.-M.;Chun-Ju Chiang;Cheng A.-L.;Lai M.-S.; Liang Y.-H.; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; CHUN-JU CHIANG; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-05-07T02:46:37Z	Young patients with colorectal cancer have increased risk of second primary cancers	YI-HSIN LIANG; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏	2021-05-07T02:46:36Z	Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study	YI-HSIN LIANG; Shao Y.-Y.; Chen H.-M.; Cheng A.-L.; Lai M.-S.; Yeh K.-H.
臺大學術典藏	2021-05-07T02:46:36Z	Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice	YI-HSIN LIANG; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-05-07T02:46:34Z	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer	YI-HSIN LIANG; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2021-05-03T02:21:08Z	Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions	Shao Y.-Y.; Hu F.-C.; JIN-TUNG LIANG; Chiu W.-T.; Cheng A.-L.; Yang C.-H.
臺大學術典藏	2021-04-27T08:36:02Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-04-27T08:36:01Z	Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors	Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; HUNG-YANG KUO; Lien M.-Y.; Shao Y.-Y.; Huang T.-C.; Hsu C.-H.
臺大學術典藏	2021-04-27T08:11:51Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-04-27T08:11:50Z	Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors	Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; HUNG-YANG KUO; Lien M.-Y.; Shao Y.-Y.; Huang T.-C.; Hsu C.-H.
臺大學術典藏	2021-04-26T01:47:25Z	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan	Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; MING-CHIH HO; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group
臺大學術典藏	2021-03-19T01:54:21Z	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma	Shao Y.-Y.; TSUNG-HAO LIU; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-19T01:54:20Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-19T01:54:20Z	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure	TSUNG-HAO LIU; Hsu C.-H.; Shao Y.-Y.
臺大學術典藏	2021-03-19T01:54:20Z	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment	Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; TSUNG-HAO LIU; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-19T01:54:19Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-19T01:54:19Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-19T01:54:17Z	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade	TSUNG-HAO LIU; Shao Y.-Y.; Hsu C.-H.
臺大學術典藏	2021-03-18T03:23:39Z	The impact of diabetes mellitus on prognosis of early breast cancer in Asia	WEI-WU CHEN; Shao Y.-Y.; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-03-18T02:02:48Z	Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study	Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-18T02:02:23Z	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment	Lu L.-C.;Lee Y.-H.;Chang C.-J.;Chia-Tung Shun;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; CHIA-TUNG SHUN; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T07:44:49Z	Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer	LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2021-03-15T07:44:49Z	Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy	Shao Y.-Y.; LI-CHUN LU; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T07:44:49Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:48Z	�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma	LI-CHUN LU; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T07:44:48Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	LI-CHUN LU; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-03-15T07:44:47Z	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy	Shao Y.-Y.; Wu C.-H.; LI-CHUN LU; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:47Z	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy	LI-CHUN LU; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:46Z	Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials	Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; LI-CHUN LU; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:45Z	Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study	Li-Chun Lu;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; LI-CHUN LU; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:45Z	Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma	Lin H.-H.; Feng W.-C.; LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:44Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:44Z	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment	Li-Chun Lu;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; LI-CHUN LU; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T07:44:43Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T07:44:43Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:42Z	Solving the deficit of cancer pain management skills by education programs	Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; LI-CHUN LU; Hsu C.-H.

显示项目 176-225 / 396 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 53303647 在线人数 : 1119 教育部委托研究计画计画执行:国立台湾大学图书馆